Indian summer for innovation?
This article was originally published in Scrip
The emergence of India's pharmaceutical industry as a global player has just moved one step further with the announcement that Sanofi is paying $50 million up front to access a monoclonal antibody developed by Glenmark Pharmaceuticals. While there have already been deals between Western pharma companies and Indian companies covering biosimilars and generics, the signing of a deal worth potentially $613 million plus royalties represents an important milestone for India's burgeoning innovative pharma industry.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.